Stimulant-Related Disorders
Resources for Patients and Caregivers
Stimulant use disorder captures a range of problems associated with the use of a wide variety of stimulant drugs, including meth, cocaine, and amphetamines, but not including caffeine or nicotine.
Cluster Number:
Wiki Number: 51-Stimulant-Related Disorders
Diagnosis:
US Patients:
World Patients:
Sex Ratio:
Age Onset:
Brain Area:
Symptoms:
Progression:
Causes:
Medications:
Therapies:
Youtube Video: Substance Related Disorders
Amazon or Library Book: The Amphetamine Debate
Click the book to link or order from Amazon.
Support Group: startyourrecovery.org; 800-662-4357
(SAMHSA-Federal Government Helpline)
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Emergency care utilization in persons with substance related diagnosesby Wayne Kepner on December 17, 2024
BACKGROUND: Substance use is a significant contributor to emergency department (ED) visits. Little is known about ED utilization patterns of individuals with substance related diagnosis (SRD). We used electronic health records (EHR) from a large healthcare system in California to examine ED healthcare utilization and socio-demographic characteristics of individuals with SRDs.
- Prevalence of adults with stimulant misuse and/or stimulant use disorder in Massachusetts, USA, 2014-2021by Joshua A Barocas on December 16, 2024
CONCLUSIONS: The estimated prevalence of stimulant misuse and/or use disorder in Massachusetts from 2014 to 2021 ranged from 4% to nearly 7% of the population. People from racial minorities appear to be disproportionately affected compared with the white non-Hispanic population. The unknown population accounted for large proportions of the total estimated population.
- Reevaluating ADHD and its First-Line Treatment: Insights from DSM-5-TR and Modern Approachesby Yaakov Ophir on November 14, 2024
Is Attention Deficit Hyperactivity Disorder (ADHD) a "brain disorder"? Should it be managed regularly with stimulant drugs? This article critically examines the evolving biomedical discourse surrounding these questions through a close inspection of the latest edition of the influential psychiatric manual - the DSM-5-TR - as well as additional authoritative sources (e.g., previous DSM editions, consensus statements, FDA communications). The DSM-5-TR acknowledges that "no biological marker is...
- Differences in the Rates of Diagnoses of Mental and Behavioral Disorders Due to Psychoactive Substance Use by Sex and Age during Pre-Pandemic and COVID-19 Pandemic Periods in Kazakhstanby Kamila Akkuzinova on October 25, 2024
CONCLUSIONS: These results indicate that further measures designed to prevent mental and behavioral disorders due to psychoactive substances are necessary at the primary, secondary, and tertiary levels, and personnel in medicine/nursing, the government, private organizations, and the public need to collaborate to devise such measures.